Pediatric Testing Requirements For Biosimilars Should Be Waived, Firms Say
Executive Summary
FDA’s draft guidance suggests that pediatric assessments under the Pediatric Research Equity Act would be required for non-interchangeable biosimilars, but not for interchangeable products.